Laura Sepp-Lorenzino
Net Worth

Last updated:

What is Laura Sepp-Lorenzino net worth?

The estimated net worth of Dr. Laura Sepp-Lorenzino is at least $22,235,019 as of 8 Jan 2024. He owns shares worth $450,252 as insider, has earned $19,347,247 from insider trading and has received compensation worth at least $2,437,520 in Intellia Therapeutics, Inc..

What is the salary of Laura Sepp-Lorenzino?

Dr. Laura Sepp-Lorenzino salary is $609,380 per year as Executive Vice President & Chief Scientific Officer in Intellia Therapeutics, Inc..

How old is Laura Sepp-Lorenzino?

Dr. Laura Sepp-Lorenzino is 64 years old, born in 1961.

What stocks does Laura Sepp-Lorenzino currently own?

As insider, Dr. Laura Sepp-Lorenzino owns shares in one company:

Company Title Shares Price per share Total value
Intellia Therapeutics, Inc. (NTLA) Executive Vice President & Chief Scientific Officer 43,927 $10.25 $450,252

What does Intellia Therapeutics, Inc. do?

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

NTLA logo
NTLA
Intellia Therapeutics, Inc.
$10.25

Laura Sepp-Lorenzino insider trading

Intellia Therapeutics, Inc.

Dr. Laura Sepp-Lorenzino has made 9 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 667 units of NTLA stock worth $19,596 on 8 Jan 2024.

The largest trade he's ever made was exercising 97,000 units of NTLA stock on 30 Aug 2021. As of 8 Jan 2024 he still owns at least 43,927 units of NTLA stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 667 $29.38 $19,596
Sale
Common Stock 1,608 $28.66 $46,085
Sale
Common Stock 5,532 $29.46 $162,973
Option
Restricted Stock Unit 3,500 N/A N/A
Option
Common Stock 3,500 N/A N/A
Sale
Common Stock 1,641 $38.22 $62,719
Sale
Common Stock 689 $39.1 $26,940
Sale
Common Stock 2,508 $37.21 $93,323
Option
Common Stock 3,500 N/A N/A
Option
Restricted Stock Unit 3,500 N/A N/A
Option
Restricted Stock Unit 3,500 N/A N/A
Sale
Common Stock 1,148 $112.25 $128,863
Option
Common Stock 3,500 N/A N/A
Sale
Common Stock 97,000 $156.7 $15,200,288
Option
Common Stock 97,000 $13.83 $1,341,025
Option
Stock Option (right to buy) 97,000 $13.83 $1,341,025
Option
Common Stock 26,000 $13.4 $348,400
Sale
Common Stock 26,000 $138.71 $3,606,460
Option
Stock Option (right to buy) 26,000 $13.4 $348,400

Intellia Therapeutics key executives

Intellia Therapeutics, Inc. executives and other stock owners filed with the SEC:

  • Dr. John M. Leonard (68) Pres, Chief Executive Officer & Director
  • Dr. Laura Sepp-Lorenzino (64) Executive Vice President & Chief Scientific Officer
  • Mr. Glenn G. Goddard (54) Executive Vice President, Chief Financial Officer & Treasurer